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A B S T R A C T
Toll-like receptors (TLRs) are the principal mediators of rapid microbial recognition: the lipopolysac-
charide (LPS) receptor TLR4 seems to have a paradigmatic role. Single nucleotide polymorphisms (SNPs)
in the TLR4 gene, such as +896A/G, known to attenuate receptor signaling, have been described. The
+896A/G SNP is signiﬁcantly less frequent in patients with myocardial infarction, Alzheimer’s disease or
prostate cancer, whereas it is overrepresented in centenarians. To clarify and conﬁrm the biological
effects of +896A/G SNP and its role in the pathophysiology of age-related diseases and longevity, we
assessed the levels of IL-6, TNF-a, IL-10 and eicosanoids (LTB4 and PGE2) in LPS-stimulated whole blood
samples in vitro of 50 young healthy Sicilians, screened for the presence of this SNP. To evaluate the
possible inﬂuence of SNPs in PTGS2 and 5-Lo genes on eicosanoid production, the enrolled individuals
were also genotyped for 765G/C PTGS2 and 1708G/A 5-Lo SNPs. Both pro-inﬂammatory cytokines
and eicosanoids were signiﬁcantly lower in carriers bearing the TLR4 mutation, whereas the anti-
inﬂammatory IL-10 values were higher. On the basis of data reported herein, some suggestions can be
drawn. First, pathogen load, by interacting with the host genotype, determines the type and intensity of
inﬂammatory responses, according to the pro-inﬂammatory status and tissue injury, implicated in the
pathophysiology of major age-related diseases. Second, adequate control of inﬂammatory response
might reduce the risk of these diseases, and, reciprocally, might increase the chance of extended survival
in an environment with reduced antigen (that is, pathogen) load.
 2011 Elsevier Ireland Ltd. All rights reserved.
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Genetic variations in innate immune response are thought to
inﬂuence the risk of several human diseases by altering host
response to environmental stress (Lin et al., 2006; Goldstein, 2009;
Hirschhorn, 2009; Kraft and Hunter, 2009). Good examples, under
current examination, are innate immune pathways. Among these,
TLR4, the key receptor for LPS, provides an ideal model. It permits
the study of the consequences of its genetic variations and their
relation to the function of the receptor pathway, and their
implications in the risk of atherosclerosis, Alzheimer’s disease (AD)
and cancer (Balistreri et al., 2009; Beutler, 2002; Uematsu and
Akira, 2008). A SNP, Asp299Gly or +896A/G (rs:4986790), has been* Corresponding author at: Gruppo di Studio sull’Immunosenescenza, Diparti-
mento di Biopatologia e Biotecnologie Mediche e Forensi dell’, Universita` di
Palermo, Corso Tukory 211, Palermo 90134, Italy. Tel.: +39 0916555911; fax: +39
0916555933.
E-mail address: crbalistreri@unipa.it (C.R. Balistreri).
0047-6374/$ – see front matter  2011 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.mad.2010.12.005identiﬁed in the TLR4 gene, encoding single amino-acid substitu-
tion in the extra-cellular receptor domain (Arbour et al., 2000). This
SNP induces a blunted innate/inﬂammatory response to both
foreign pathogens and endogenously generated inﬂammatory
ligands (Arbour et al., 2000; Balistreri et al., 2009; Schro¨der and
Schumann, 2005). In particular, it may inﬂuence inﬂammatory
responses and the risk of major age-related diseases affecting the
production of inﬂammatory mediators.
Cytokines and eicosanoids represent the key regulators of
innate/inﬂammatory response. High serum or plasma levels of
these molecules have been correlated with the major age-related
diseases, conﬁrming their role in atherosclerosis, AD and cancer
pathophysiology (Akiyama et al., 2000; Boyce, 2008; Bruunsgaard
et al., 2001; Candore et al., 2007a,b; Caruso et al., 2009; Krabbe
et al., 2004; Leon, 2007; Rogers, 2008; Sheu et al., 2008). However,
the magnitude of cytokine and eicosanoid production has been
shown to vary individually and is likely based on genetic
heterogeneity (Bucova et al., 2008; Candore et al., 2007a,b; Caruso
et al., 2009; Grimble, 2003; Rea et al., 2006; Reyes-Gibby et al.,
2008). This might determine changes in the innate/inﬂammatory
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involved in the development and progression of age-related
diseases (Bucova et al., 2008; Candore et al., 2007a,b; Caruso
et al., 2009; Grimble, 2003; Rea et al., 2006; Reyes-Gibby et al.,
2008). Hence, certain people develop diseases and others remain
healthy. One or more functional SNPs in one or more genes
might be responsible. Accordingly, recent studies have sug-
gested the role of +896A/G TLR4 SNP in cytokine and eicosanoid
production (Arbour et al., 2000; Ferwerda et al., 2007, 2008;
Hoshino et al., 1999; Michel et al., 2003; Norata et al., 2005;
Poltorak et al., 1998; von Aulock et al., 2003; Werner et al.,
2003). On the other hand, an association of this TLR4 SNP with
an increased risk of Gram negative infections and septic shock
has been demonstrated (Agnese et al., 2002; Lorenz et al., 2002;
Schro¨der and Schumann, 2005). However, contrasting data have
been obtained in other studies (Child et al., 2003; Erridge et al.,
2003; Read et al., 2001; Heesen et al., 2003; Imahara et al.,
2005; Schippers et al., 2005; von Aulock et al., 2003; Yang et al.,
2004).
Changes in eicosanoid levels are also correlated with SNPs in
the promoter region of PTGS2 and 5-Lo genes, respectively
codifying the cyclooxygenase-(Cox)-2 and 5-lipoxygenase (5-Lo),
enzymes involved in arachidonic acid metabolism. Two functional
(765G/C PTGS2 and 1708G/A 5-Lo) SNPs have recently been
identiﬁed and associated with the major age-related diseases
(Candore et al., 2007a,b; Caruso et al., 2009; Cipollone et al., 2004;
In et al., 1997; Orbe et al., 2006).
To clarify and conﬁrm the possible pathophysiological effects of
+896A/G TLR4 SNP (Balistreri et al., 2004, 2008, 2010), we analysed
the levels of IL-6, TNF-a, IL-10 and eicosanoids (LTB4 and PGE2) in
LPS-stimulated whole blood samples in vitro of 50 young healthy
Sicilians, screened for the presence of +896A/G TLR4 SNP. To
evaluate the possible inﬂuences of SNPs in PTGS2 and 5-Lo genes
on eicosanoid production, we also screened the enrolled individu-
als for the 765G/C PTGS2 and 1708G/A 5-Lo SNPs. Hence, our
idea was to test whether the three SNPs have a major inﬂuence on
the production of inﬂammatory mediators, when they operate in
combination to create a ‘‘risk proﬁle,’’ as suggested in our previous
studies (Candore et al., 2007a,b; Caruso et al., 2009).
2. Materials and methods
2.1. Population studied and TLR4, PTGS2 and 5-Lo genotyping
The study included 50 Sicilian Caucasoids from Palermo and neighbourhood (age
range: 25–50 years; 24 females and 26 males), in good health according to their
clinical history and blood tests (complete blood cell count, erythrocyte
sedimentation rate, glucose, urea nitrogen, creatinine, electrolytes, C reactive
protein, liver function tests, iron, proteins). They have previously been genotyped
for the following SNPs: +896A/G TLR4 SNP, 765G/C PTGS2 SNP (rs:20417) and
1708 G/A 5-Lo SNP (no available rs designation) (Table 1). The procedures for
detecting these SNPs have previously been described (Balistreri et al., 2005; Listı`
et al., 2008). Of 50 individuals, 40 were homozygous for wild-type alleles of +896A/
G TLR4 SNP, and 10 had one or two +896G alleles. Furthermore, 30 out 40 were also
homozygous for wild-type alleles of765G/C PTGS2 and1708G/A 5-Lo SNPs, and
of 10 carriers with one or two +896A/G alleles, 6 also had one or two 765C PTGS2
and 1708A 5-Lo alleles.
The study received approval from local ethics committees and all participants
gave their informed consent.Table 1
Genes (accession number), SNPs (accession number), and substitutions investigated in
Genes SNPs Biologica
TLR4 (NM-138554.1) +896A/G (Asp299Gly; rs4986790) Determin
domain a
pathogen
PTGS2 (NM-000963)
(Cox-2 gene)
765G/C (rs20417) Located
a reducti
5-Lo (NM-000698) 1708G/A (no rs available designation) Modifyin2.2. Whole blood assay
Venous EDTA blood samples were collected from all subjects under basal
conditions at 9.00 am. Within 4 h, using aseptic handling, the ﬁrst series of blood
aliquots (900 ml) of each sample was placed in sterile 1.5 ml Eppendorf tubes and
stimulated with 1 g/ml of Escherichia coli LPS (serotype 055:B5, L6529-1MG,
Sigma–Aldrich, St. Louis, MO, USA). A second series of blood aliquots (900 ml) of the
same samples was not stimulated with LPS. Both series of blood aliquots were
gently vortexed for 5 s and incubated with open lids for 4, 24, and 48 h at 37 8C, in
5% CO2 and humidiﬁed air. The samples were incubated for different times (4, 24
and 48 h), because preliminary results showed different kinetics in the several
assays. A different relationship between the TLR4 allele effect and times of
incubation (4, 24 and 48 h) was, indeed, observed. After induction, 500 ml of RPMI-
1640 (with 25 mM Hepes and L-glutamine, Gibco, Breda, The Netherlands) was
added to each sample. The samples were brieﬂy vortexed and centrifuged for 3 min
at 10,000 rpm and the supernatant (900 ml) was transferred to new Eppendorf
tubes. The samples were then ﬂash frozen in ethanol and dry ice and stored at
80 8C, until the enzyme-linked immunosorbent assay (ELISA) test was performed.
2.3. LPS contaminations: Limulus Amebocyte Lysate (LAL)-chromo end-point test
To detect and quantify the probable LPS contaminations in supernatants of the
cultures under baseline conditions (LPS unstimulated) from both low (+896G+) and
high (+896A+) responder cells at 4, 24 and 48 h, the Limulus Amebocyte Lysate
(LAL)-chromo end-point test was utilised (International PBI, Milano, Italy). The test
was performed according to the manufacturer’s instructions. Results were
expressed as pg/ml. Detection limit in our laboratory was 0.005 pg/ml.
2.4. Cytokine and eicosanoid assays
IL-6, TNF-a, IL-10, LTB4 and PGE2 supernatant levels were determined by ELISA
(R&D System, Abingdon, Oxon, UK). All tests were performed according to the
manufacturer’s instructions. To standardize our results, reference preparations of
IL-6, TNF-a, IL-10, LTB4 and PGE2 were tested in all assays. Results were expressed
as pg/ml. Detection limits in our laboratory were 1.6 pg/ml for IL-6, 2.1 pg/ml for
TNF-a, 3.9 pg/ml for IL-10, 18.2 pg/ml for PGE2 and 13.7 pg/ml for LTB4.
2.5. Statistical analysis
LPS levels were expressed as median (range). To detect the possible correlations
between the subliminal LPS levels and the production of cytokines, the non-
parametrical Spearman correlation test was used. The quantitative values of the
cytokines and eicosanoids were expressed asmean  SD and presented on a log scale
in the ﬁgures. To assess the differences in cytokine and eicosanoid production between
low and high responder cells, the analysis of variance (ANOVA) test (corrected by
Bonferroni) was utilised. Values of p < 0.05were considered signiﬁcant. To identify the
possible correlations between the mediator levels and times of incubation, the non-
parametrical Spearman correlation test was also used.
3. Results
3.1. LPS contamination
LPS contamination in supernatants of cell cultures at baseline
conditions from both low (+896G+) and high (+896A+) responder
subjects was detected at all times. LPS levels were 0.142 pg/ml
(0.102–0.208). A positive correlation was observed between LPS
and IL-6 and TNF-a levels in supernatants of cell cultures from
subjects with high (+896A+) responder SNP (n = 40, r = 0.433,
p < 0.001 and r = 0.33, p < 0.013, respectively, data not shown).
Furthermore, a negative correlationwas found between LPS and IL-
10 levels in supernatants of cultures under baseline conditions
from high (+896A+) responder cells, consistent with the reducedthe study.
l effect
ing a single amino acid substitution in the extracellular receptor
nd, hence, a blunted innate/inﬂammatory response to both foreign
s and endogenously generated inﬂammatory ligands (Balistreri et al., 2009)
within a putative binding site for the transcription factor Sp1, determining
on in the expression of Cox-2 enzyme (Cipollone et al., 2004; Orbe et al., 2006)
g gene transcription with an increased protein expression (In et al., 1997)
Fig. 1. (A) IL-6 levels (pg/ml) produced by cells, from subjects with the wild-type
allele (+896A+) and with the +896G allele (+896G+), at baseline conditions or
stimulated for 4, 24, 48 h in whole blood assay with 1 g/ml LPS. Comparing the IL-6
values between +896G+ vs. +896A+ cells at baseline conditions and after LPS
stimulation signiﬁcant differences were obtained at all times (p < 0.001). (B) TNF-a
levels (pg/ml) produced by cells, from subjects with the wild-type allele (+896A+)
and with the +896G allele (+896G+), stimulated for 4, 24, 48 h in whole blood assay,
with 1 g/ml LPS or at baseline conditions. The comparison of the TNF-a values
between stimulated +896G+ vs. +896A+ cells demonstrated signiﬁcant differences:
at 4 h and 24 h (p < 0.001), and at 48 h (p < 0.01). Comparing the TNF-a levels
between the +896G+ cultures and those with +896A allele at baseline conditions,
signiﬁcant differences were observed at all times (p < 0.001). (C) IL-10 levels (pg/
ml) produced by cells, from subjects with the wild-type allele (+896A+) and with
the +896G allele (+896G+), stimulated for 4, 24, 48 h inwhole blood assay, with 1 g/
ml LPS or at baseline conditions. Comparing its values between the stimulated
+896G+ vs. +896A+ cells signiﬁcant differences were obtained at all times
(p < 0.001). Comparing values between +896G+ vs. +896A+ cells at baseline
conditions, signiﬁcant differences were observed: at 4 h (p < 0.05), at 24 h
(p < 0.001) and at 48 h (p < 0.01).
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cultures (n = 10, r = 0.203, p = 0.023, data not shown). Thus, the
possible reasons for this correlation might be the important
contribution of biological effect of the SNP.
3.2. Data of cytokine production
Signiﬁcant differences in IL-6 and TNF-a levelswere obtained at
all times and both at baseline conditions and after LPS stimulation
between cell cultures from subjectswithwild-type allele and those
with the +896G allele (Fig. 1A and B). In particular, signiﬁcant
higher levels of both pro-inﬂammatory cytokines at all times and
at baseline conditions and after LPS stimulation were detected in
supernatants of cell cultures from individuals with the +896A wild
type allele respect to those detected in the supernatant of cell
cultures from subjects with +896G allele at baseline conditions and
after LPS stimulation. This comparison demonstrated the following
signiﬁcant differences: 5.22  1.5 at 4 h, 9.49  1.4 at 24 h,
12.66  2.1 at 48 h pg/ml IL-6 levels at baseline conditions and
631  17.9 at 4 h, 823  12.1 at 24 h, 887  14.2 at 48 h pg/ml IL6
after LPS stimulation for +896A+ cells vs. 1.71  0.5 at 4 h, 2.15  0.7
at 24 h, 1.62  0.2 pg/ml IL-6 levels at baseline conditions and
439  22.6 at 4 h, 555  23.4 at 24 h, 539  21.2 at 48 h for +896G+
cells; 7.71  1.27 at 4 h, 19.45  3.73 at 24 h and 20.23  5.1 at
48 h pg/ml TNF-a levels at baseline conditions and 779.35  15.1 at
4 h, 581.82  32.2 at 24 h, 480.94  30 at 48 h for +896A+ cells vs.
2.46  0.9 at 4 h, 6.78  1.1 at 24 h, 12.34  3.8 at 48 h pg/ml TNF-a
levels at baseline conditions and 296.25  13.8 at 4 h, 344.4  28.2 at
24 h, 239  17.1 at 48 h pg/ml TNF-a levels after LPS stimulation for
+896G+ cells.
Furthermore, the comparison of IL-10 levels between the
cultures with +896G allele and those with wild type allele at
baseline conditions or after LPS stimulation showed signiﬁcant
differences (Fig. 1C). In particular, signiﬁcant higher levels of the
IL-10 anti-inﬂammatory cytokine were detected at all times in
supernatants of cell cultures from subjects with +896G allele at
baseline conditions (4.96  2.21 at 4 h, 7.81  1.6 at 24 h,
10.15  4.9 at 48) and after LPS stimulation (9.53  4.6 at 4 h,
11.32  3 at 24 h and 8.04  3.28 at 48 h) respect to those observed in
the supernatants of the cell cultures from subjects with +896A wild
type allele at baseline conditions (2.87  0.5 at 4 h, 3.98  2.at 24 h
and 3.3  1.1 at 48 h) and after LPS stimulation (3.65  1.6 at 4 h,
4.06  1.7 at 24 h and 3.04  1.4 at 48 h).
In addition, a positive correlationwas identiﬁed between the IL-
6 values and the times of incubation after LPS stimulation in cell
cultures with the wild type allele (r = 0.367, p < 0.001), char-
acterised by a signiﬁcant different relationship of its levels
between 4 and 48 h and a critical peak at 48 h (Table 2). No
signiﬁcant correlationswere detected between the other cytokines
and the times of incubation after LPS stimulation (data not shown).
3.3. Data of eicosanoid production
The analysis of the eicosanoid levels showed signiﬁcant higher
PGE2 levels at all times among the cell cultures with the wild type
allele both at baseline (385  52 at 4 h, 652  75 at 24 h, 686  34 at
48) and LPS stimulated conditions (1235  145.8 at 4 h, 2085  238.9
at 24 h, 3188  312.9). The comparison of PGE2 levels between the
cultures with wild type allele and those with +896G allele at baseline
conditions (155.8  8 at 4 h, 229  9 at 24 h, 81  8.9) or after LPS
stimulation (375  45.8 at 4 h, 455  38.9 at 24 h, 198  12.9)
demonstrated, indeed, signiﬁcant differences (Fig. 2A). In addition,
a positive correlation was observed between the PGE2 values and the
times of incubation in the stimulated LPS cell cultures with the wild
type allele (r = 0.428, p < 0.0001), characterised by a critical peak at
48 h (Table 2).Furthermore, the comparison of LTB4 values between the
+896G+ (90  6 at 4 h, 119  45.5 at 24 h, 107  41.8 at 48 h) vs.
+896A+ (315  45.7 at 4 h, 489  52.5 at 24 h, 345  64.7 at 48 h)
cells showed signiﬁcant differences at baseline conditions (see
Fig. 2B). In contrast, the comparison of LTB4 values between the
stimulated +896G+ (567  44.9) vs. +896A+ (734  73.8) cells
Table 2
Signiﬁcant correlations of pro-inﬂammatory mediator levels in the subjects with wild type allele (+896A+) with the times of LPS stimulation.
LPS stimulation Levels at 4h Levels at 24h Levels at 48h r p values
IL-6 63117.9 82312.1 88714.2 0.367 <0.001
PGE2 1235145.8 2085238.9 3188312.9 0.428 <0.0001
LTB4 42325.6 50567.9 73473.8 0.167 <0.01
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correlation was found between the LTB4 values and the times of
LPS incubation in the cultures with the wild type allele (r = 0.167,
p < 0.01).
In order to evaluate the possible biological effects of SNPs in
PTGS2 and 5-Lo genes on eicosanoid production, we also screened
the enrolled individuals for the 765G/C PTGS2 and 1708G/A 5-
Lo SNPs. Accordingly, signiﬁcant higher PGE2 levels were found
among the cell cultureswith the765Gwild type allele at all times
and both at baseline conditions (380  45.8 at 4 h, 489  38.9 at
24 h, 560  12.9 48 h) and after LPS stimulation (3340  56 at 4 h,
4590  78 at 24 h, 4790  67 at 48 h) respect to thosewith the765C
variant allele (765C+) both at baseline conditions (56.2  4.8 at 4 h,
39.9  3.9 at 24 h, 128  12.9 at 48 h) and stimulated (310  7.8 atFig. 2. (A) PGE2 levels (pg/ml) produced by cells, from subjects with the wild-type
allele (+896A+) and with the +896G allele (+896G+), stimulated for 4, 24, 48 h in
whole blood assay, with LPS (1 g/ml) or at baseline conditions. The analysis of PGE2
values between stimulated +896G+ vs. +896A+ cells showed signiﬁcant differences
at all times (p < 0.001). Comparing its values between +896G+ vs. +896A+ cells at
baseline conditions, signiﬁcant differences were observed: at 4 h (p < 0.05), at 24 h
(p < 0.01) and at 48 h (p < 0.01). (B) LTB4 levels (pg/ml) produced by cells, from
subjects with the wild-type allele (+896A+) and with the +896G allele (+896G+),
stimulated for 4, 24, 48 h in whole blood assay, with LPS (1 g/ml) or at baseline
conditions. Comparing LTB4 values between stimulated +896G+ vs. +896A+ cells,
signiﬁcant differences were only obtained at 48 h (p < 0.01). Comparing LTB4
values between +896G+ vs. +896A+ cells at baseline conditions, signiﬁcant
differences were found at all times (p < 0.001).4 h, 369  11.9 at 24 h, 410  20.8 at 48 h) (Fig. 3A). A positive
correlation was observed between the PGE2 levels and the times of
LPS incubation in the cell cultures with the 765G wild type allele
(r = 0.201, p < 0.01).
Screening for1708G/A 5-Lo SNP, signiﬁcant higher LTB4 levels
were obtained among the cell cultures with the 1708A allele
(1708A + 5-Lo) at all times and only at baseline conditions
(232  15.7 at 4 h, 301  12.5 at 24 h, 417  14.7 at 48 h) respect to
those (45  6 at 4 h, 198  15.5 at 24 h, 101  11.8) detected among
the cell cultures from subjectswith thewild-type1708G (1708G+)
allele (Fig. 3B). The comparison of the LTB4 levels among the
stimulated cell cultures demonstrated no signiﬁcant differences.
Furthermore, we stratiﬁed the subjects studied according to the
combined presence of +896A/G TLR4 SNP with the two SNPs in
PTGS2 and 5-Lo genes, to test the possible inﬂuence of the three
SNPs on the eicosanoid release, creating a ‘‘risk proﬁle’’.
Accordingly, all possible combinations of the three SNPs have
been considered. The comparison of PGE2 levels between
+896A + TLR4/765G + PTGS2 (‘‘high responder’’ genotype) vs.
+896G + TLR4/765C+ (‘‘low responder’’ genotype) PTGS2 cells at
stimulated (815  145.8 at 4 h, 1085  238.9 at 24 h, 2089  312.9
at 48 h vs. 298  45.8 at 4 h, 397  38.9 at 24 h, 165  12.9 at 48 h,
respectively) and baseline conditions (245  52 at 4 h, 542  75 at
24 h, 609  34 vs. 101  8 at 4 h, 193  9 at 24 h, 72  8.9,
respectively) showed signiﬁcant differences at all times (Fig. 4A).
The same results were observed by comparing the LTB4 levels
between +896A + TLR4/1708A + 5-LO (‘‘high responder’’ genotype)
vs. +896G + TLR4/1708G + 5-LO (‘‘low responder’’ genotype) cells at
stimulated (421  67.9 at 4 h, 498  61 at 24 h, 681  44.9 at 48 h vs.
182  45.7 at 4 h, 322  52.5 at 24 h, 296  64.7 at 48 h, respectively)
and baseline conditions (212  67.9 at 4 h, 318  61 at 24 h,
468  44.9 vs. 65  6 at 4 h, 102  45.5 at 24 h, 137  41.8 at
48 h) (Fig. 4B).
In addition, positive correlations were observed between the
PGE2 and LTB4 levels and the times of LPS stimulation (r = 0.509,
p < 0.0001 and r = 0.199, p < 0.01, respectively) in the cell cultures
with +896A + TLR4/-765G + PTGS2 (‘‘high responder’’ genotype)
and between +896A + TLR4/1708A + 5-LO (‘‘high responder’’
genotype), respectively.
4. Discussion
Current evidence supports the involvement of innate immunity
and inﬂammation in the pathophysiology of major age-related
diseases (Caruso et al., 2005; Licastro et al., 2005; Vasto et al.,
2007). Different mediators, i.e. pro-inﬂammatory cytokines and
eicosanoids, display a crucial role in atherosclerosis, neurodegen-
eration and carcinogenesis. Their production and release have
prevalently been associated with the activation of TLR4 receptor
(Balistreri et al., 2009; Candore et al., 2007; Caruso et al., 2009). In
other words, the TLR4 receptor, activated by pathogens or
endogenous molecules, would have the role of hub in the
inﬂammatory responses involved in the pathophysiology of these
diseases (Balistreri et al., 2009; Vasto et al., 2007). On the other
hand, this suggestion is supported by a signiﬁcant correlation
between the +896A/G SNP and atherosclerosis, AD and prostate
cancer (Balistreri et al., 2004, 2008, 2010).
Fig. 3. (A) PGE2 levels (pg/ml) produced by cells, from subjects with the wild-type
allele (765G + PTGS2) and with the 765C allele (765C+), stimulated for 4, 24,
48 h in whole blood assay, with LPS (1 g/ml) or at baseline conditions. Signiﬁcant
differences were obtained at all times (p < 0.001), comparing the PGE2 values
between the cultures with thewild-type765G allele (765G+) and thosewith the
765C variant allele (765C+) both at stimulated and baseline conditions. (B) LTB4
levels (pg/ml) produced by cells, from subjects with the wild-type allele (1708G+)
and with the 1708A allele (1708A + 5-Lo), stimulated for 4, 24, 48 h in whole
blood assay, with LPS (1 g/ml) or at baseline conditions. The comparisons of the
LTB4 values between the cultureswith thewild-type1708G (1708G+) and those
with the 1708A variant allele (1708A+) both at stimulated and baseline
conditions demonstrated signiﬁcant differences at all times (precisely at 4 h
(p < 0.01), 24 h (p < 0.05) and 48 h (p < 0.001)) and only at baseline conditions.
Fig. 4. (A) PGE2 levels (pg/ml) produced by cells, from subjects with the
+896A + TLR4/765G + PTGS2 ‘‘high responder’’ genotype (pro-inﬂammatory
proﬁle) and subjects with +896G + TLR4/765C + PTGS2 ‘‘low responder’’
genotype (anti-inﬂammatory proﬁle), stimulated for 4, 24, 48 h in whole blood
assay with LPS (1 g/ml) or at baseline conditions. Comparing the quantitative PGE2
values of cultures both at stimulated and baseline conditions from +896A + TLR4/
765G + PTGS2 vs. +896G + TLR4/765C + PTGS2 cells, signiﬁcant differences were
observed at all times (p < 0.001). (B) LTB4 levels (pg/ml) produced by cells, from
subjects with the +896A + TLR4/1708A + 5-LO ‘‘high responder’’ genotype (pro-
inﬂammatory proﬁle) and subjects with +896G + TLR4/1708G + 5-LO ‘‘low
responder’’ genotype (anti-inﬂammatory proﬁle), stimulated for 4, 24, 48 h in
whole blood assay with LPS (1 g/ml) or at baseline conditions. The comparison
between the cultures from +896A + TLR4/1708A + 5-LO vs. +896G + TLR4/
1708G + 5-LO cells both at stimulated and baseline conditions demonstrated
signiﬁcant differences at 4 h (p < 0.001) and 48 h (p < 0.05) after LPS stimulation
and at all times at baseline condition (p < 0.05).
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TLR4 SNP to modify the intensity of inﬂammatory responses, in
this report LPS-mediated production of the pro- and anti-
inﬂammatory cytokines (IL-6, TNF-a and IL-10) and eicosanoids
(LTB4 and PGE2) has been detected in whole blood samples of 50
healthy Sicilians, genotyped for +896A/G TLR4, 765G/C PTGS2
and 1708G/A 5-Lo SNPs. Signiﬁcantly higher levels of pro-
inﬂammatory IL-6 and TNF-a cytokines have been produced by
cells of individuals with the wild-type +896A TLR4 allele (+896A+).
We have also observed signiﬁcantly higher eicosanoid levels
produced in wild-type subjects compared to +896G carriers.
Signiﬁcantly higher levels of LTB4 and PGE2 were also detected, by
stratifying the subjects for the presence of PTGS2 and 5-Lo SNPs, or
for the combined presence of +896A/G TLR4 SNP and PTGS2 and 5-
Lo SNPs. On the other hand, this strengthens our suggestion that
pro-inﬂammatory TLR4 SNPs might have a major inﬂuence on the
production of inﬂammatory mediators, when they operate in
combination to create a ‘‘risk proﬁle’’ (Balistreri et al., 2008, 2010;
Candore et al., 2007a,b; Caruso et al., 2009).
The data obtained conﬁrm a strong effect of +896A/G TLR4 SNP
on the production of pro-inﬂammatory cytokines, as well as in
modulating eicosanoid production. They also conﬁrm the impor-
tant implications of PTGS2 and 5-Lo SNPs in the production ofthese molecules. On the whole, the data obtained on pro-
inﬂammatory cytokines and eicosanoids are consistent with the
ﬁndings showing increased levels of these molecules in vessel
lesions, senile plaques and tumour tissues (Balistreri et al., 2009;
Bostock et al., 2009; Caruso et al., 2009; Davila and Hibberd, 2009;
Srivastava et al., 2009; Yandell et al., 2008).
Another interesting result of this study is represented by
signiﬁcantly higher levels of anti-inﬂammatory IL-10 cytokine
produced by cells of carriers of the +896G TLR4 allele. This seems to
C.R. Balistreri et al. /Mechanisms of Ageing and Development 132 (2011) 86–92 91evidence the capacity of the +896G TLR4 allele to mediate a better
control of inﬂammatory responses induced by chronic stimuli, so
likely decreasing the effects of atherogenetic damage, amyloid
peptide insult and prostate carcinogens (Balistreri et al., 2009;
Candore et al., 2007; Caruso et al., 2009; Vasto et al., 2007). The
principal function of IL-10 is to limit and ultimately to terminate
the inﬂammatory signal. Several lines of evidence indicate a
regulatory role of IL-10 in the development and progression of the
major age-related diseases (Lio and Caruso, 2006). On the other
hand, a higher frequency of +896G TLR4 allele has been observed in
centenarians compared to patients affected by the major age-
related diseases, as demonstrated in our studies (Balistreri et al.,
2004, 2009, 2010). This supports the data obtained in our previous
studies showing that genetic background controlling inﬂammation
might play an opposite role in cardiovascular diseases (CVD), AD,
prostate cancer and in longevity. People genetically predisposed to
weak inﬂammatory activity, have less chance of developing CVD,
AD and prostate cancer and, therefore, without any complication of
serious infectious disease, have a chance of living longer (Candore
et al., 2007a,b; Caruso et al., 2009; Vasto et al., 2007).
Some literature data agree with the results of our study, while
others show contrasting results (Arbour et al., 2000; Child et al.,
2003; Erridge et al., 2003; Heesen et al., 2003; Imahara et al., 2005;
Michel et al., 2003; Norata et al., 2005; Read et al., 2001; Schippers
et al., 2005;Werner et al., 2003; von Aulock et al., 2003; Yang et al.,
2004). The different associations between the genotypes of +896A/
G SNP and the levels of inﬂammatory mediators evidenced in
different studies may be ascribed to some factors. The ﬁrst
limitation might derive from the small number of individual
carriers of TLR4 SNPs enrolled in some studies, with different
number of homozygous and heterozygous individuals, compared
to the wild-type carriers. The heterozygous and homozygous state
is necessary to determine differences in the response to LPS
stimulation tested. The cause might be attributed to the reduced
frequency of the TLR4 SNPs in the individuals analysed and
possibly because they belong to no ethnically homogenous
population. A second limitation of these studies might be the
different models used. Several factors, such as CD14, LPS-binding
protein (LBP) and serum HDL may modulate in the in vitro studies
changing LPS recognition and binding to TLR4 receptor. Their inter-
individual difference in levels may inﬂuence the LPS response and
the production and release of inﬂammatory mediators. Other
limitations may be ascribed to the in vitromethod used for the LPS
stimulation. The easy and reproducible technique commonly
performed in the in vitro studies is the whole blood assay.
Nevertheless, it presents unfavourable aspects, such as the
impossibility of correcting the inter-individual differences in
number of leukocytes (in particular of the peripheral blood
mononuclear cells) and to reduce the effects of soluble factors,
such as CD14, LBP, serum HDL (as above described), able to modify
the LPS signaling. In addition, different serotypes of LPS are utilised
in the various studies. However, it remains less clear whether they
can determine a different response. In contrast, correlations
between the different LPS concentrations and the production of
inﬂammatory mediators have been observed in several studies
(Erridge et al., 2003; Heesen et al., 2003; Imahara et al., 2005;
Schippers et al., 2005; von Aulock et al., 2003).
On the basis of data reported herein, some suggestions can be
drawn. Pathogen load, by interacting with the host genotype,
determines the type and the intensity of inﬂammatory responses
accountable for pro-inﬂammatory status and tissue injury, known
to be implicated in the pathophysiology of the major age-related
diseases, such as CVD, AD and cancer (Balistreri et al., 2009).
Second, adequate control of inﬂammatory response might reduce
the risk of these age-related diseases, and, reciprocally, it might
increase the chance of extended survival in an environment withreduced antigen (that is, pathogen) load (Balistreri et al., 2009;
Candore et al., 2007a; Vasto et al., 2007). Accordingly, a higher
frequency of the anti-inﬂammatory +896G TLR4 allele has been
observed in centenarians (Balistreri et al., 2004).
A long life in a healthy, vigorous, youthful body has always been
one of humanity’s greatest dreams. Recent progress in genetic
manipulations and calorie-restricted diets in laboratory animals
hold forth the promise that some day science might enable us to
exert total control over our biological ageing (Jirillo et al., 2008).
However, it is becoming clear that the control of inﬂammation
plays a central role in delaying age-related inﬂammatory diseases
and in the attainment of longevity.
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